公开(公告)号：US06486196B2

公开(公告)日：2002-11-26

申请号：US09849586

申请日：2001-05-04

申请人： Srinivas Nanduri ,  Sairam Pothukuchi ,  Sriram Rajagopal ,  Venkateswarlu Akella ,  Sunilkumar Bhadramma Kochunarayana Pillai ,  Ranjan Chakrabarti

发明人： Srinivas Nanduri ,  Sairam Pothukuchi ,  Sriram Rajagopal ,  Venkateswarlu Akella ,  Sunilkumar Bhadramma Kochunarayana Pillai ,  Ranjan Chakrabarti

IPC分类号： A61K31335

CPC分类号： C07D407/06 ,  C07D307/34

摘要： The present invention relates to novel anticancer agents, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, and their pharmaceutically acceptable solvates. The present invention more particularly relates to novel derivatives of andrographolide, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, and their pharmaceutically acceptable solvates. The novel derivatives of andrographolide have the general formula (I).

摘要翻译： 本发明涉及新型抗癌剂，其立体异构体，其多晶型物，其药学上可接受的盐及其药学上可接受的溶剂合物。 本发明更具体地涉及穿心莲内酯的新型衍生物，其立体异构体，其多晶型物，其药学上可接受的盐及其药学上可接受的溶剂合物。 穿心莲内酯的新衍生物具有通式（I）。

公开(公告)号：US06410590B1

公开(公告)日：2002-06-25

申请号：US09775533

申请日：2001-02-01

申请人： Srinivas Nanduri ,  Sriram Rajagopal ,  Sairam Pothukuchi ,  Sunilkumar Bhadramma Kochunarayana Pillai ,  Ranjan Chakrabarti

发明人： Srinivas Nanduri ,  Sriram Rajagopal ,  Sairam Pothukuchi ,  Sunilkumar Bhadramma Kochunarayana Pillai ,  Ranjan Chakrabarti

IPC分类号： A61K31341

CPC分类号： C07D407/06

摘要： The present invention relates to novel derivatives of Andrographolide, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, and their pharmaceutically acceptable solvates. The novel derivatives of Andrographolide have the general formula (I) The andrographolide derivatives represented by general formula (I) are useful for treating cancer, HSV, HIV, psoriasis, restonosis, atherosclerosis, other cardiovascular disorders, and can be used as antiviral, antimalarial, antibacterial, hepatoprotective, and immunomodulating agents and for treatment of other metabolic disorders.

摘要翻译： 本发明涉及穿心莲内酯的新衍生物，其立体异构体，其多晶型物，其药学上可接受的盐及其药学上可接受的溶剂合物。 穿心莲内酯的新型衍生物具有通式（I）由通式（I）表示的穿心莲内酯衍生物可用于治疗癌症，HSV，HIV，牛皮癣，再狭窄，动脉粥样硬化，其他心血管疾病，可用作抗病毒，抗疟药 ，抗菌，肝保护和免疫调节剂和治疗其他代谢紊乱。

公开(公告)号：US06576662B2

公开(公告)日：2003-06-10

申请号：US09849584

申请日：2001-05-04

申请人： Srinivas Nanduri ,  Sriram Rajagopal ,  Venkateswarlu Akella

发明人： Srinivas Nanduri ,  Sriram Rajagopal ,  Venkateswarlu Akella

IPC分类号： A61K3134

CPC分类号： C07D405/06 ,  C07D307/58 ,  C07D405/08 ,  C07D405/12 ,  C07D417/12

摘要： The present invention relates to novel anticancer agents, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, and their pharmaceutically acceptable solvates. The present invention more particularly relates to novel derivatives of andrographolide, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, and their pharmaceutically acceptable solvates. The novel derivatives of andrographolide have the general formula (I).

公开(公告)号：US08440662B2

公开(公告)日：2013-05-14

申请号：US13285227

申请日：2011-10-31

申请人： Roger Astbury Smith ,  Scott Kevin Thompson ,  Subramanya Hosahalli ,  Mallesham Bejugam ,  Srinivas Nanduri ,  Sunil Kumar Panigrahi ,  Natarajan Mahalingam

发明人： Roger Astbury Smith ,  Scott Kevin Thompson ,  Subramanya Hosahalli ,  Mallesham Bejugam ,  Srinivas Nanduri ,  Sunil Kumar Panigrahi ,  Natarajan Mahalingam

IPC分类号： A61K31/535 ,  C07D413/04 ,  C07D413/14

CPC分类号： C07D239/72 ,  A61K31/535 ,  C07D239/42 ,  C07D295/155 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D405/04 ,  C07D405/14 ,  C07D409/04 ,  C07D413/04 ,  C07D413/14 ,  C07D471/04

摘要： The present application provides novel substituted quinazoline and pyrido-pyrimidine compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating PI3K and/or mTOR activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the PI3K/AKT/mTOR pathway. Advantageously, these compounds perform as dual PI3K/mTOR inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.

公开(公告)号：US20120129851A1

公开(公告)日：2012-05-24

申请号：US13285227

申请日：2011-10-31

申请人： Roger Astbury Smith ,  Scott Kevin Thompson ,  Subramanya Hosahalli ,  Mallesham Bejugam ,  Srinivas Nanduri ,  Sunil Kumar Panigrahi ,  Natarajan Mahalingam

发明人： Roger Astbury Smith ,  Scott Kevin Thompson ,  Subramanya Hosahalli ,  Mallesham Bejugam ,  Srinivas Nanduri ,  Sunil Kumar Panigrahi ,  Natarajan Mahalingam

IPC分类号： A61K31/5377 ,  C07D413/04 ,  C07D471/04 ,  A61P29/00 ,  A61P35/02 ,  A61P11/00 ,  A61P9/10 ,  A61P1/00 ,  A61P35/00 ,  C07D413/14 ,  A61P19/02

CPC分类号： C07D239/72 ,  A61K31/535 ,  C07D239/42 ,  C07D295/155 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D405/04 ,  C07D405/14 ,  C07D409/04 ,  C07D413/04 ,  C07D413/14 ,  C07D471/04

摘要： The present application provides novel substituted quinazoline and pyrido-pyrimidine compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating PI3K and/or mTOR activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the PI3K/AKT/mTOR pathway. Advantageously, these compounds perform as dual PI3K/mTOR inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.

摘要翻译： 本申请提供新的取代喹唑啉和吡啶并嘧啶化合物及其药学上可接受的盐。 还提供了制备这些化合物的方法。 通过向患者施用治疗有效量的一种或多种化合物，这些化合物可用于共同调节PI3K和/或mTOR活性。 通过这样做，这些化合物在治疗与PI3K / AKT / mTOR途径失调相关的病症中是有效的。 有利地，这些化合物表现为双重PI3K / mTOR抑制剂。 可以使用这些化合物治疗各种病症，并且包括以炎症或异常细胞增殖为特征的疾病。 在一个实施方案中，该疾病是癌症。